trending Market Intelligence /marketintelligence/en/news-insights/trending/nbzmofqtbtjayq8ltff6og2 content esgSubNav
In This List

Intec Pharma raises $2M from underwriters of its public offering

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Intec Pharma raises $2M from underwriters of its public offering

Intec Pharma Ltd. said the underwriters of its public offering partially exercised their overallotment option to buy 400,000 additional shares at $5.25 apiece.

The Israel-based clinical stage biopharmaceutical company received net proceeds of about $2 million from the exercise.

In April, Intec closed its public offering of 6.75 million ordinary shares at $5.25 apiece to raise about $35.4 million in gross proceeds.

Oppenheimer & Co. Inc. acted as the sole book-running manager, while Ladenburg Thalmann and Roth Capital Partners acted as co-managers in the offering.